

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

6488.US.02

SERIAL NO.

09/709,829

APPLICANT

Steven L. Krill *et al.*

FILING DATE

November 10, 2000

GROUP

1653

(37 CFR 1.98 (b))

JC892 U.S. PTO
09/709829

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
JR	A1	5 8 8 9 0 5 1	03/30/99	Chen, <i>et al.</i>	514	530	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
JR	B1	0 8 5 2 1 4 0	08/07/98	EP			
JR	B2	9 7 4 6 2 2 2	12/12/97	WO			
JR	B3	9 7 0 6 7 8 1	02/02/97	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

JR	C1	W. L. Chiou, <i>et al.</i> , "Pharmaceutical Applications of Solid Dispersion System", JOURNAL OF PHARMACEUTICAL SCIENCES, 60 (9), (1971), 1281-1302
JR	C2	J. L. Ford, "The Current Status of Solid Dispersions", PHARM ACTA HELV. 61. Nr. 3, (1986) 69-88
JR	C3	B. J. Aungst, <i>et al.</i> , "Improved Oral Bioavailability of an HIV Protease Inhibitor Using Celucire 44/14 and Labrasol Vehicles", B.T. GATTETOSSE, 87 (1994), 49-54
JR	C3	B. J. Aungst, <i>et al.</i> , "Amphiphilic Vehicles Improve the Oral Bioavailability of a Poorly Soluble HIV Protease Inhibitor at High Doses", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 156 (1997) 79-88

EXAMINER

Jeffrey E. Russell

DATE CONSIDERED

February 15, 2002

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)